Oramorph (Morphine Sulfate Pentahydrate)

Morphine sulfate pentahydrate binds to μ‑opioid receptors in the central nervous system, activating G‑protein pathways that inhibit adenylate cyclase, reduce calcium entry, increase potassium efflux, and suppress neuronal firing. This decreases transmission of pain signals and enhances descending inhibitory pathways, resulting in analgesia.

The dosage of Oramorph is individualized by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, age, renal and hepatic function, and other clinical factors. The prescriber determines the appropriate starting dose, titration schedule, and maximum daily limit, and adjustments are made according to therapeutic response and tolerability.

Safety of morphine sulfate during pregnancy and lactation has not been definitively established; it is classified as a pregnancy category unknown. Opioids can cross the placenta and may be excreted in breast milk, potentially causing respiratory depression in the newborn. Use only if the potential benefit justifies the potential risk and under medical supervision.

To request Oramorph, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required cold‑chain handling), and assistance with import documentation.

Oramorph, containing morphine sulfate, is a prototypical μ‑opioid receptor agonist and is often considered the gold standard for severe pain. Compared with synthetic opioids such as fentanyl or oxycodone, morphine has a longer half‑life, a well‑characterized safety profile, and is available in multiple oral formulations, but may cause more constipation and histamine‑mediated reactions.

Oramorph should be stored at ambient temperature, below 25 °C, in its original container, protected from moisture, light, and excessive heat. Keep the product out of reach of children and unauthorized persons. Do not crush or split tablets unless specifically instructed, and dispose of any unused medication according to local regulations.

Oramorph is administered orally, typically as a tablet or solution, and should be taken exactly as prescribed. The dose may be given at regular intervals or as needed for breakthrough pain, depending on the clinician’s instructions. Swallow tablets whole with water unless an oral solution is provided, and avoid chewing unless directed.

The most serious risks of Oramorph include respiratory depression, severe hypotension, profound sedation, and the potential for dependence or abuse. Patients with compromised respiratory function, the elderly, or those taking other CNS depressants are at higher risk. Prompt medical attention is required if breathing becomes shallow or consciousness is impaired.

Oramorph is contraindicated in patients with known hypersensitivity to morphine or other opioids, those with significant respiratory depression, acute or severe asthma, and in individuals who have taken monoamine oxidase inhibitors within the past 14 days. Caution is also advised for patients with severe hepatic or renal impairment, and it should not be used in children unless specifically indicated.